ClinicalTrials.gg
CompletedNCT00139750Updated Jun 4, 2007

12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation

A Phase 2 interventional study of CP-526,555 (varenicline) in Smoking Cessation, sponsored by Pfizer. Completed at 15 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-06-04.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.

Enrollment
23rd of 110
600 · median 209
Started
2004
the only one that year
Phase 2
18 of 110
none open now
Registered
1st of 110
by date
Lead sponsor
26 of 110
Pfizer

Among the 110 studies testing varenicline in Smoking Cessation, this one is the 23rd largest by enrollment, is the only one that started in 2004, is one of 18 in phase 2, and was the 1st registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing varenicline in Smoking Cessation, or all of them as a file.
02

Study summary

The purpose of the study is to examine the safety and efficacy and dose-response relationship of three doses of CP-526,555 for 12 weeks compared with placebo for smoking cessation; including post-treatment follow-up of smoking status to one year from randomization. A small satellite protocol (A3051048) investigated safety of a second course of therapy in subjects who did not quit.

03

Conditions studied

  • Smoking Cessation

Browse trials for

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cigarette smokers who are motivated to stop smoking and have smoked an average of at least 10 cigarettes per day

Exclusion criteria

Exclusion Criteria:

  • Subjects who have used a nicotine replacement product within 30 days of the study screening visit or intend to use it during the study.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
600 participants

Interventions

06

What researchers measure

Primary outcomes

  1. 4-week continuous quit rate (CQR) for Weeks 9-12

Secondary outcomes

  1. Continuous abstinence for Weeks 9-52 and Weeks 9-24

  2. Long-term quit rate at Week 52

  3. 4-week CQR for Weeks 4-7

  4. 7-day point prevalence of asbtinence Weeks 12, Week 24, and Week 52

  5. Continuous abstinence from TQD (Week 1) through Week 12

  6. Weekly average number of cigarettes smoked per day for Weeks 1-12

  7. Evaluation of withdrawal symptoms by the Minnesota Nicotine Withdrawal Scale

  8. Evaluation of smoking satisfaction by the Smoking Effects Inventory

  9. Evaluation of urge to smoke by the Brief Questionnaire of Smoking Urges

07

Study locations

15 sites
  • Pfizer Investigational Site
    Noda, Chiba, Japan
  • Pfizer Investigational Site
    Sapporo, Hokkaido, Japan
  • Pfizer Investigational Site
    Yokohama, Kanagawa, Japan
  • Pfizer Investigational Site
    Beppu-shi, Oita-ken, Japan
  • Pfizer Investigational Site
    Toyonaka, Osaka, Japan
  • Pfizer Investigational Site
    Tosu, Saga, Japan
  • Pfizer Investigational Site
    Hamamatsu, Shizuoka, Japan
  • Pfizer Investigational Site
    Edogawa-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Minato-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Musashino, Tokyo, Japan
  • Pfizer Investigational Site
    Setagaya-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Shinagawa-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Toshima-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Fukuoka, Japan
  • Pfizer Investigational Site
    Ohita, Japan
08

References and documents

Publications

  • Nakamura M, Oshima A, Ohkura M, Arteaga C, Suwa K. Predictors of lapse and relapse to smoking in successful quitters in a varenicline post hoc analysis in Japanese smokers. Clin Ther. 2014 Jun 1;36(6):918-27. doi: 10.1016/j.clinthera.2014.03.013. Epub 2014 May 5. PubMed 24811751 ↗
  • Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther. 2007 Jun;29(6):1040-56. doi: 10.1016/j.clinthera.2007.06.012. PubMed 17692720 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2005
First posted
Aug 31, 2005
Start
Dec 2004
CompletionActual
Feb 2006
Last update
Jun 4, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00139750
Lead sponsor
Pfizer
First posted
Aug 31, 2005
Start date
Dec 2004
Completion
Feb 2006
Last update
Jun 4, 2007

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion